Everything you need to know about new ‘game-changer’ Ozempic rival that promises even MORE weight loss

Retatrutide, a triple-hormone injection developed by Eli Lilly, produced an average weight loss of 15.3% in patients with type 2 diabetes and 24.2% in those with obesity during clinical trials, according to data published in The Lancet and the New England Journal of Medicine.

The drug targets three metabolic hormones—GIP, GLP-1, and glucagon—to lower blood sugar and reduce body weight. While not yet FDA-approved, trial results show it may outperform current single- and dual-hormone medications used for metabolic health.

How does retatrutide differ from Ozempic and Mounjaro?

Retatrutide is the first medication in its class to target three hormone pathways. Ozempic targets one (GLP-1), while Mounjaro targets two (GIP and GLP-1), according to trial data.

The addition of glucagon is the primary differentiator. According to the source, while GLP-1 and GIP suppress appetite and slow digestion, glucagon may increase energy expenditure and promote fat burning.

This triple-action approach correlates with higher weight loss figures. Data shows Ozempic typically causes a 5% to 15% weight loss, and Mounjaro leads to a 15% to 22% range. In a phase 2 obesity trial, retatrutide’s 12 mg dose resulted in an average weight loss of 24.2%, or roughly 52 pounds.

What were the results for type 2 diabetes patients?

The TRANSCEND-T2D-1 trial, published in The Lancet, enrolled 537 adults with early type 2 diabetes. Participants receiving the 12 mg dose achieved an average weight loss of 15.3%, though an “efficacy estimand” assuming perfect adherence put that figure at 16.9%.

Blood sugar control also improved. Nearly 90% of participants on the 12 mg dose reached a target HbA1c of less than 7%, and 40% achieved a normal level below 5.7%, according to the study.

Researchers also noted improvements in other cardiometabolic markers. Systolic blood pressure dropped by about 5mmHg in retatrutide groups, and triglycerides fell by up to 34%.

What are the side effects and safety risks?

Gastrointestinal issues were the most common side effects. Participants reported nausea, diarrhea, vomiting, and constipation, particularly during the initial weeks of dose increases.

Some participants experienced a temporary increase in heart rate that peaked around 24 weeks before declining. Others reported mild skin sensitivity.

The study reported no cases of severe hypoglycemia, severe pancreas inflammation, or thyroid cancer. Discontinuation rates due to adverse events remained low, between 2% and 5%.

When will retatrutide be available?

The drug is currently being studied in a large phase 3 program called TRIUMPH. These trials are expected to conclude throughout 2026.

Following the completion of these trials, Eli Lilly may submit a New Drug Application. Because the FDA typically takes six to ten months to review such applications, approval is likely not to occur until 2027.

Why is the drug being sold without FDA approval?

A CBS News investigation found dozens of clinics openly advertising retatrutide. Some physicians source the drug from licensed compounding pharmacies in Texas and Florida.

Scott Brunner, CEO of the Alliance for Pharmacy Compounding, told CBS News there are “zero” legal grounds for compounding an experimental drug that has never been approved.

Other consumers purchase “research-grade” vials online for approximately $675. These products often arrive as a powder that users mix with bacteriostatic water at home, bypassing FDA oversight for purity and safety.

Frequently Asked Questions

What is the difference between retatrutide and Zepbound?
Retatrutide targets three hormones (GIP, GLP-1, and glucagon), whereas tirzepatide (sold as Zepbound) targets two. In trials, retatrutide’s 12 mg dose showed a 24.2% weight loss in people with obesity, compared to 20.9% for tirzepatide.

Can retatrutide reverse prediabetes?
According to the TRANSCEND-T2D-1 trial, 72% of participants who had prediabetes at the start of the study returned to normal blood sugar levels after 40 weeks of treatment.

Is retatrutide safe to buy online as “research-grade”?
The FDA has stated there is no legal justification for compounding this experimental drug. “Research-grade” products come from unregulated suppliers and are not subject to FDA oversight for safety or purity.

Do you believe the potential for higher weight loss justifies the risks of using non-FDA-approved medications?